These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 21707288)

  • 21. Chromophobe renal cell carcinoma: histomorphologic characteristics and evaluation of conventional pathologic prognostic parameters in 145 cases.
    Amin MB; Paner GP; Alvarado-Cabrero I; Young AN; Stricker HJ; Lyles RH; Moch H
    Am J Surg Pathol; 2008 Dec; 32(12):1822-34. PubMed ID: 18813125
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chemotherapy for renal cell carcinoma.
    Amato RJ
    Semin Oncol; 2000 Apr; 27(2):177-86. PubMed ID: 10768596
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Everolimus in the treatment of renal cell carcinoma and neuroendocrine tumors.
    Chan HY; Grossman AB; Bukowski RM
    Adv Ther; 2010 Aug; 27(8):495-511. PubMed ID: 20623346
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Are we really making an advance in the treatment of metastatic renal cell carcinoma?
    Kirkali Z
    Eur Urol; 2006 Apr; 49(4):604-5. PubMed ID: 16481098
    [No Abstract]   [Full Text] [Related]  

  • 25. Optimizing treatment for metastatic renal cell carcinoma.
    Patard JJ; Porta C; Wagstaff J; Gschwend JE
    Expert Rev Anticancer Ther; 2011 Dec; 11(12):1901-11. PubMed ID: 22117157
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New systemic treatment options for metastatic renal-cell carcinoma in the era of targeted therapies.
    Tan TH; Pranavan G; Haxhimolla HZ; Yip D
    Asia Pac J Clin Oncol; 2010 Mar; 6(1):5-18. PubMed ID: 20398033
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Understanding the importance of smart drugs in renal cell carcinoma.
    Patard JJ; Rioux-Leclercq N; Fergelot P
    Eur Urol; 2006 Apr; 49(4):633-43. PubMed ID: 16481093
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chromophobe renal cell carcinoma with sarcomatoid dedifferentiation treated with pazopanib: a case report.
    Matrana MR; Ng C; Rao P; Lim ZD; Tannir NM
    Clin Genitourin Cancer; 2011 Dec; 9(2):137-9. PubMed ID: 21831725
    [No Abstract]   [Full Text] [Related]  

  • 29. Predictive factors of response to treatment in patients with metastatic renal cell carcinoma: new evidence.
    Tonini G; Fratto ME; Imperatori M; Pantano F; Vincenzi B; Santini D
    Expert Rev Anticancer Ther; 2011 Jun; 11(6):921-30. PubMed ID: 21707289
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sorafenib therapy for metastatic renal carcinoma in patients with low cardiac ejection fraction: report of two cases and literature review.
    Kamada P; Dudek AZ
    Cancer Invest; 2010 Jun; 28(5):501-4. PubMed ID: 20014944
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sarcomatoid renal cell carcinoma in a young adult.
    Kourda N; Zeddini A; Zaafrani MR; Zermani R; Ferchichi L; Ayed M; Jilani SB
    Pathologica; 2006 Jun; 98(3):181-3. PubMed ID: 17036947
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sarcomatoid differentiation of renal cell carcinoma: a clinical case with literature review.
    Kountourakis P; Kandylis K; Daskalopoulou D; Rigatos G
    J BUON; 2008; 13(2):281-3. PubMed ID: 18555479
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New perspectives in the treatment of metastatic renal cell carcinoma.
    Barrière J; Hoch B; Ferrero JM
    Crit Rev Oncol Hematol; 2012 Dec; 84 Suppl 1():e16-23. PubMed ID: 22099727
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Medullary renal cell carcinoma and response to therapy with bortezomib.
    Ronnen EA; Kondagunta GV; Motzer RJ
    J Clin Oncol; 2006 Mar; 24(9):e14. PubMed ID: 16549825
    [No Abstract]   [Full Text] [Related]  

  • 35. Prognostic factors and survival of patients with sarcomatoid renal cell carcinoma.
    Mian BM; Bhadkamkar N; Slaton JW; Pisters PW; Daliani D; Swanson DA; Pisters LL
    J Urol; 2002 Jan; 167(1):65-70. PubMed ID: 11743277
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Renal cell carcinoma in children and adolescents.
    Spreafico F; Collini P; Terenziani M; Marchianò A; Piva L
    Expert Rev Anticancer Ther; 2010 Dec; 10(12):1967-78. PubMed ID: 21110762
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Grade 4 unclassified renal cell carcinoma with sarcomatoid component expressing S-100 protein. A case report with peculiar diagnostic and therapeutic implications.
    Miolo G; Ash A; Buonadonna A; Lo Re G; Torrisi E; Cervo S; Santeufemia DA; Tuzi A; Canzonieri V
    Cancer Biol Ther; 2014; 15(11):1439-43. PubMed ID: 25482943
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Biomarker for molecular targeting therapy against renal cell carcinoma].
    Mizuno R; Oya M
    Gan To Kagaku Ryoho; 2012 Jan; 39(1):39-42. PubMed ID: 22454982
    [No Abstract]   [Full Text] [Related]  

  • 39. Acquired cystic disease-associated renal cell carcinoma with sarcomatoid change and rhabdoid features.
    Kuroda N; Tamura M; Hamaguchi N; Mikami S; Pan CC; Brunelli M; Martignoni G; Hes O; Michal M; Lee GH
    Ann Diagn Pathol; 2011 Dec; 15(6):462-6. PubMed ID: 21036640
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High-dose interleukin-2 therapy for metastatic renal cell carcinoma and metastatic melanoma: still the standard.
    Dutcher JP
    Oncology (Williston Park); 2011 Apr; 25(5):427-8. PubMed ID: 21710841
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.